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Abstract
 Purpose—Positive energy imbalance and growth factors linked to obesity promote the 
phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway. As the 
obesity-breast cancer associations differ between European-American (EA) and African-American 
(AA) women, we investigated genetic variants in the mTOR pathway and breast cancer risk in 
these two racial groups.
 Methods—We examined 400 single nucleotide polymorphisms (SNPs) in 31 mTOR pathway 
genes in the Women’s Circle of Health Study with 1263 incident breast cancers (645 EA, 618 AA) 
and 1382 controls (641 EA, 741 AA). Multivariable logistic regression was performed separately 
within racial groups. Effect modification was assessed for measured body size and weight gain 
since age 20.
 Results—In EA women, variants in FRAP1 rs12125777 (intron), PRR5L rs3740958 
(synonymous-coding), and CDKAL1 rs9368197 (intron) were associated with increased breast 
cancer risk, while variants in RPTOR rs9900506 (intron) were associated with decreased risk 
(nominal P-trend for functional and FRAP1 SNPs or P adjusted for correlated test [PACT] <0.05). 
For AA women, variants in RPTOR rs3817293 (intron), PIK3R1 rs7713645 (intron), and 
CDKAL1 rs9368197 were associated with decreased breast cancer risk. The significance for 
FRAP1 rs12125777 and RPTOR rs9900506 in EA women did not hold after correction for 
multiple comparisons. The risk associated with FRAP1 rs12125777 was higher among EAs who 
had body mass index ≥30 kg/m2 (odds ratio=7.69, 95% CI=2.11–28.0; P-interaction=0.007) and 
gained weight ≥35 lb. since age 20 (odds ratio=3.34, 95% CI=1.42–7.85; P-interaction=0.021), 
compared to their counterparts.
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 Conclusions—The mTOR pathway may be involved in breast cancer carcinogenesis 
differently for EA and AA women.
Keywords
mammalian target of rapamycin; single nucleotide polymorphisms; breast cancer; gene-
environment interaction; body size; African Americans
 Introduction
Obesity has been implicated in the development of breast cancer [1]. Body mass index 
(BMI), a measurement of general obesity, is positively associated with breast cancer risk 
among postmenopausal women, but not in premenopausal women [1,2]. The risk in 
postmenopausal women may also vary by breast cancer subtype defined by hormone 
receptor status. BMI has been more often associated with an increased risk of estrogen 
receptor positive (ER+) than of ER negative (ER−) breast cancer in postmenopausal women 
[2]. These observations are mainly derived from women of European ancestry. Among 
postmenopausal African American (AA) women, BMI is positively associated with ER+ 
breast cancer risk. However, it is inversely associated with ER− and triple-negative (ER−, 
progesterone receptor [PR] negative, and human epidermal growth factor receptor [Her-2/
neu] negative) breast cancer risks in postmenopausal AA women [3,4]. In addition, waist-to-
hip ratio (WHR), an indicator of abdominal obesity, may be important in increasing risk for 
both ER subtypes of breast cancer [4] in both pre- and postmenopausal AA women [4–7]. 
Although several hypotheses that incorporate hormonal and inflammatory factors have been 
proposed, the mechanisms underlying the influence of obesity on breast cancer risk are not 
fully understood [8].
Among various obesity-related pathological pathways, the phosphatidylinositol 3-
kinase/AKT/mammalian target of rapamycin (PI3K-AKT-mTOR or mTOR) pathway has 
been linked to cancer hallmarks [9]. Because a key role of the mTOR pathway is to maintain 
cellular energy homoeostasis, it is activated when the energy content of the diet is greater 
than energy expended by the body, i.e., positive energy imbalance [10]. The regulation of 
energy homeostasis occurs in the mTOR complex 1 (mTORC1), which initiates various 
downstream responses, including modulation of ER transcriptional activity (Figure 1) [9,11]. 
In addition, growth factors, e.g., glucose and insulin, can signal mTOR complex 2 
(mTORC2) and influence cell metabolism and survival through AKT (protein kinase B). In 
breast cancer, somatic mutations in the mTOR pathway are commonly observed [12]. A few 
studies have examined associations between genetic polymorphisms in the mTOR pathway 
and breast cancer risk among European women [13,14]. However, these studies have 
focused only on a small number of genes (i.e., TSC1, TSC2, and LAMTOR). It is currently 
unknown whether the genetic variants in other key mTOR pathway elements, such as the 
mTOR coding gene FRAP1, affect breast cancer risk. In addition, the role of obesity in the 
possible association of the mTOR pathway with breast cancer risk warrants investigation, 
especially since a positive energy imbalance has been shown to exert effect modification on 
the association between mTOR pathway genes and risk of kidney and bladder cancers 
[15,16].
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The objective of this study was to assess the association of genetic variants in the mTOR 
pathway with breast cancer risk. Given that the mTOR pathway can be activated by positive 
energy imbalance and growth factors, both of which are directly associated with obesity and 
weight gain, we examined whether BMI, WHR, and weight gain in adulthood modified the 
association of genetic variants in the mTOR pathway and breast cancer risk. Because there 
are differences in breast cancer risks associated with obesity between race, ER status, and 
menopausal status, we analyzed the data for European American (EA) and AA women 
separately and conducted exploratory stratified analyses according to ER and menopausal 
status.
 Methods
 Study population
The Women’s Circle of Health Study (WCHS) is an ongoing multi-site case-control study in 
New York City and New Jersey. WCHS was designed to evaluate genetic and lifestyle risk 
factors for both early and aggressive breast cancer and to compare the distribution of these 
factors in EA and AA women [17,18]. Breast cancer cases were women with primary, 
histologically confirmed invasive breast cancer or ductal carcinoma in situ (DCIS) diagnosed 
within 9 months of recruitment. Other inclusion criteria were self-identified EA and AA 
women, 20–75 years of age, literate in English, and with no previous history of cancer other 
than non-melanoma skin cancer. In New York City, cases were identified through 
collaborations with hospitals that had a large AA patient base, and in NJ, cases were 
ascertained through the State Cancer Registry using rapid case ascertainment. Controls had 
the same inclusion criteria plus no history of cancer and were identified during the same 
time period as the cases. Controls were ascertained by random digit dialing and frequency 
matched with cases by 5-year age groups, race, and telephone exchanges (area code plus 3-
digit prefixes, for cases from New York City) or county of residence (for cases from New 
Jersey). In New Jersey, AA controls were also recruited through outreach sources such as 
health events [18]. Information on ER status was from pathology reports. Questionnaire, 
anthropometric, and genetic data from 1279 cases (658 EA, 621 AA) and 1392 controls (649 
EA, 743 AA) recruited during 2002–2011 were available from WCHS. Of these, 26 women 
(16 cases and 10 controls) were excluded due to missing data on BMI or other covariates, 
leaving 1,263 cases (645 EA, 618 AA) and 1,382 controls (641 EA, 741 AA) in the 
statistical analyses of genetic associations. In addition, 68 women (41 cases and 27 controls) 
with missing data on WHR and weight gain were excluded, leaving 1,222 cases (634 EA, 
588 AA) and 1,355 controls (631 EA, 724 AA) women in the effect modification analysis. 
The WCHS protocol was approved by institutional review boards at Roswell Park Cancer 
Institute, the Cancer Institute of New Jersey, Mount Sinai School of Medicine, and 
participating hospitals in New York. Signed informed consent was obtained from each 
participant prior to interview and biospecimen collection.
 DNA collection and genotyping
Blood samples were initially collected for DNA extraction, but after enrollment of 
approximately 850 participants, saliva samples were collected as a source of DNA due to 
cost restrains. Genomic DNA was extracted from whole blood using the FlexiGeneTM DNA 
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isolation kits (Qiagen Inc., Valencia, CA) and, from saliva, Oragene™ kits (DNA Genotek 
Inc., Kanata, Ontario, Canada). DNA was evaluated and quantitated by Nanodrop UV-
spectrometer (Thermo Fisher Scientific Inc., Wilmington, DE) and PicoGreen-based 
fluorometric assay (Molecular Probes, Invitrogen Inc., Carlsbad, CA), and stored at −80°C 
until analysis.
We selected 27 protein-coding genes in the mTOR pathway (Supplementary Table 1) and 
additionally, 4 insulin and obesity related-genes (CDKAL1, CYB5R4, GIP, and IRS1) 
known to have upstream influences on energy-balance regulation [19]. We selected a set of 
representative single nucleotide polymorphisms (tagSNPs) that had high correlation (r2 
≥0.8) with other variants within a given linkage disequilibrium (LD) bin, were present at a 
minor allele frequency (MAF) of ≥0.05 in at least one reference population and were within 
10 kb upstream of the 5′-untranslated region (UTR) and 10 kb downstream of the 3′-UTR of 
the gene using SNPinfo [20]. Within SNPinfo, we employed reference populations (CEU 
and ASW) in HapMap2 to determine the LD structure and allelic correlations [21]. In 
addition, we also included SNPs with either known or predicted functional changes based on 
the literature. A total of 425 SNPs were attempted for genotyping.
Genotyping was performed using the Illumina GoldenGate platform (Illumina Inc., San 
Diego, CA) at Roswell Park Cancer Institute. For quality control, 5% blinded duplicates and 
two sets of in-house trio samples were included across all plates. The concordance among 
blind duplicate pairs was greater than 99.9%. SNPs were excluded if they had <90% call 
rate, <5% MAF for both EAs and AAs, or Hardy-Weinberg equilibrium (HWE) p<0.0001. 
Subsequently, 400 SNPs passed these filters and were included in statistical analyses 
(Supplementary Table 6). LD structures of the samples were assessed among EA and AA 
controls separately using Genome Variation Server 138 (University of Washington, Seattle, 
WA). To account for population admixture, all samples were also genotyped for a validated 
panel of 100 ancestry informative markers (AIMs) [22]. Based on the AIM data, proportions 
of European Ancestry and African Ancestry for each individual were computed using the 
Bayesian Markov chain Monte Carlo clustering algorithm implemented in the STRUCTURE 
program [23].
 Epidemiological data collection
In-person interviews and anthropometric measurements were conducted with a standardized 
protocol [3]. The interview covered a comprehensive set of established and suspected risk 
factors for breast cancer. For the current study, data on demographics, history of benign 
breast disease, reproductive and menstrual histories, family history of breast cancer in a first-
degree relative and cigarette smoking were utilized. Interviewers also queried participants’ 
weight and height one year before diagnosis (for cases) or reference date (for controls) and 
at every 10 years since the age of 20. Anthropometric measurements were taken at the end of 
the interview by trained staff with standing height measured once to the nearest 0.1 cm. To 
minimize measurement error, waist and hip circumferences were measured twice to the 
nearest 0.1 cm; a third measurement was taken if the difference between the first and second 
measurement was >2 cm. The 2 (or 3) measurements were averaged for analyses. 
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Measurements were not taken due to refusal, pregnancy >3 months, or physical 
impairments.
 Statistical analyses
Characteristics of cases and controls were compared with t-tests for continuous variables and 
chi-square tests for categorical variables. Logistic regression was used to estimate odds 
ratios (OR) and 95% confidence intervals (CI) adjusted for age, proportion of European 
ancestry, education, BMI, family history of breast cancer, history of benign breast disease, 
age at menarche, parity, breastfeeding, menopausal status, and smoking status. We adjusted 
for the proportion of European ancestry only in models for both EA and AA women. We did 
not adjust the proportion of African ancestry for AA women because the proportions of 
African ancestry and European ancestry add up to 1 in our data and thus the results would 
have remained the same if adjusting for African ancestry. A more general codominant 
inheritance model was initially assumed to avoid imposing a structure on the response 
expected for each additional copy of the variant allele. We also tested a dominant model, but 
did not test recessive models because the number of participants homozygous for the rare 
variant allele was small for some SNPs based on genotype distributions in EA women. P-
values for trend were calculated by coding variant alleles based on the number of rare alleles 
(0, 1, 2) and analyzed as a continuous variable in regression to subsequently test for an 
additive model. P-values for trend were adjusted for correlated tests (PACT) at the gene-level 
to account for multiple comparisons [24]. We prioritized all 15 SNPs (2 nonsynonymous) in 
FRAP1, our main hypothesized gene, plus 14 nonsynonymous SNPs and 35 high-functional 
SNPs, i.e., RegulomeDB score from 1 to 3 (Supplementary Table 7) [25], in the other genes. 
A nominal P-trend <0.05 was considered significant for this set of SNPs. For tagSNPs, a 
PACT <0.05 was considered significant. For significant SNPs, we further estimated ORs for 
ER+ and ER− breast cancer risk. P-values for heterogeneity were calculated using case-case 
logistic regression models comparing ER subtypes. Because the MAFs and LD structure in a 
large proportion of SNPs differed between EAs and AAs (Supplementary Table 6), all 
analyses were conducted separately by race.
To assess effect modification on genetic associations by obesity, we conducted stratified 
analyses by BMI, WHR, and weight change since the age of 20 years for the significant 
SNPs. BMI was calculated as the measured weight (kg) divided by height (m)2 and 
categorized as <25 (underweight to normal), 25–<30 (overweight), and ≥30 kg/m2 (obese), 
according to the World Health Organization (WHO) International Classification. WHR was 
also calculated from the measured values of waist and hip circumferences and categorized 
into ≤0.85 (normal) and >0.85 (abdominal obesity) [26]. Weight change since age 20 was 
derived from current measured weight minus self-reported weight at age 20. Weight change 
was a priori categorized into <10, 10–<25, 25–<35, ≥35 lb. BMI, WHR, and adulthood 
weight gain were mutually adjusted to reduce the influence of the other two variables on risk 
estimates. A sensitivity analysis without the mutual adjustment of body size and weight gain 
was performed because these measurements may be collinear. P values for interaction were 
obtained using Wald tests for the product term of SNP and body size or weight gain 
variables; 36 tests were performed (six SNPs times three body size/weight gain variables 
times two racial groups). A combined EA and AA model was built to assess the interaction 
Cheng et al. Page 5
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
between race and SNPs. Statistical analyses were performed using SAS 9.4 software. 
Functional exploration of significant SNPs was performed using the Encyclopedia of DNA 
Elements (ENCODE) data [27].
 Results
Table 1 presents the characteristics of cases and controls separately for EA and AA women. 
EA cases were more likely to have a first-degree relative diagnosed with breast cancer 
(P=0.001), but less likely to have a college or post-graduate degree (P<0.001) and to 
breastfeed (P=0.008), compared to EA controls. Among both cases and controls, AAs were 
more likely to be obese than EAs (52.1% vs 28.0% in cases, and 53.2% vs 27.0% in 
controls). For both EAs and AAs, cases were more likely to have history of benign breast 
disease (P=0.001 and P<0.001, respectively). For AA women, there were a higher proportion 
of current smokers in controls than cases (P<0.001). The categories of BMI, WHR, and 
weight gain from age 20 did not differ by case status in either racial group. Among those 
with known ER status of breast tumors, AA cases had a higher proportion of ER− tumors 
compared to EA cases (31.5% versus 17.2%).
Table 2 lists associations of SNPs with breast cancer in either EA or AA women. In FRAP1, 
the variant A allele of rs12125777 was associated with a higher risk of breast cancer in EAs 
(ORGA/AA vs. GG=1.69, 95% CI=1.08–2.64; nominal P-trend=0.020; PACT=0.17), but not in 
AAs. In regulatory associated protein of mTOR complex 1 (RPTOR), two SNPs that 
potentially have regulatory functions were associated with breast cancer risk. The variant G 
allele of RPTOR rs9900506 (Regulome DB score=3a) was associated with a lower breast 
cancer risk in EA women (ORGG vs. AA=0.68, 95% CI=0.48–0.95; nominal P-trend=0.042; 
PACT=0.89), but not in AA women. However, the variant of RPTOR rs3817293 (Regulome 
DB score=2b) was associated with a lower breast cancer risk in AA women (ORAA/GA vs. GG 
=0.79, 95% CI=0.63–0.99; nominal P-trend=0.044; PACT=0.97), but not in EA women. 
Among the other tagSNPs, the variant allele of rs7713645 in the phosphoinositide-3-kinase, 
regulatory subunit 1 (PIK3R1) was associated with a lower risk of breast cancer in AA 
women (ORCC vs. AA=0.56, 95% CI=0.33–0.97; PACT=0.041), while proline rich 5 like 
(PRR5L) rs3740958 was associated with a higher risk in EA women (ORGG/GA vs. AA=1.71, 
95% CI=1.29–2.27 for; PACT=0.005). In addition, CDK5 regulatory subunit-associated 
protein 1-like 1 (CDKAL1) rs9368197 was associated with a higher risk of breast cancer in 
EA women (ORAA vs. CC=1.66, 95% CI=1.08–2.54; nominal P-trend 0.032; PACT was not 
applicable because only one SNP was genotyped in this gene). The increased risk was 
mainly driven by the increase in risk of ER+ tumors, and not of ER− tumors (P-
heterogeneity=0.021; Supplementary Table 2). However, the association was reversed in AA 
women (ORAA/AC vs. CC=0.70, 95% CI=0.51–0.97; nominal P-trend=0.015). The 
associations with overall breast cancer were significantly different between EA and AA 
women for PRR5L rs3740958 and CDKAL1 rs9368197 (P-interaction of SNP and race 
<0.001 and 0.005, respectively)
Among these SNPs associated with breast cancer risk, significant effect modification of BMI 
and weight gain was observed for FRAP1 rs12125777 in EA women (Table 3). Our data 
showed that among EA women, the association of GA/AA vs. GG genotypes and breast 
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cancer risk was stronger among overweight women (25 ≤BMI <30; OR=2.37, 95% 
CI=0.91–6.13) and obese women (BMI ≥30; OR=7.69, 95% CI=2.11–28.0), compared to 
normal/underweight women (BMI <25; OR=0.85, 95% CI=0.45–1.61; p-interaction = 
0.007). The 95% CIs, however, were wide due to a small number of cases in women with the 
rare allele. A similar pattern of effect modification was also observed for weight gain since 
age 20. The association for those carrying the variant A allele of rs12125777 was 
strengthened among EA women who gained 35 lbs. or more since age 20 (OR=3.34, 95% 
CI=1.42–7.85), compared to the associations among those with lesser weight gain (P-
interaction=0.021). In the model without mutual adjustment of the three variables, the risk 
estimates were more conservative and 95% confidence intervals were narrower (e.g., 
OR=5.68, 95% CI=1.78–18.1 for GA/AA vs. GG in BMI ≥30 among EA women), 
compared to models with mutual adjustment (OR=7.69, 95% CI=2.11–28.0). 
(Supplementary Table 3). The observed effect modification of body size and weight gain 
seemed more pronounced for ER− breast cancer risk than for ER+ breast cancer risk 
(Supplementary Table 4), although the sample size was small after the stratification and thus 
these estimates were likely not precise. Effect modification of body size and weight gain was 
not observed in AA women for this SNP (Table 3), or for the other significant SNPs in either 
racial group (data not shown).
 Discussion
In this study, FRAP1 rs12125777, RPTOR rs9900506 and rs3817293, PIK3R1 rs7713645, 
PRR5L rs3740958, and CDKAL1 rs9368197 were associated with breast cancer risk in 
either EA or AA women. The associations for FRAP1 and RPTOR SNPs in EA women 
were not significant after adjusting for multiple comparisons and thus should be interpreted 
with caution. With a limited number of tests on the hypothesized gene-environment 
interaction, we observed a potential effect modification of BMI and weight gain on the 
association of FRAP1 rs12125777 with breast cancer risk in EA women. To our knowledge, 
this is the first study to examine the relationship between the mTOR pathway and breast 
cancer risk in both EA and AA women and to assess potential gene-environment 
interactions.
mTOR and RPTOR are core protein elements of mTORC1 and our data suggest that three 
SNPs in their coding genes may be associated with breast cancer risk. Based on the 
ENCODE data, FRAP1 rs12125777 is located in a region with active transcriptional 
promoters in mammary epithelial cells and DNase hypersensitivity sites in mammary gland 
(Supplementary Table 5). The SNP also maps a region potentially altering the motifs of ER-
alpha expression. Two correlated SNPs, FRAP1 rs2536 (3′-UTR) and rs12116957 (intron), 
also map to regions annotated with many transcription factors. RPTOR rs9900506 is located 
in a region with weak transcriptional enhancers. RPTOR rs9900506 was examined for the 
risk of renal cell carcinoma, although there was no evidence of an association [15]. The 
regulatory function of RPTOR rs3817293 is unclear. These SNPs in FRAP1 and RPTOR 
have not been reported in studies of breast cancer risk and warrant replication.
We also observed that the variant of rs3740958 in PRR5L, also known as PROTOR2, was 
associated with increased breast cancer risk in EA women. PROTOR2 protein is part of 
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mTORC2. PRR5L rs3740958 is a synonymous coding SNP and located within known 
functional elements. According to ENCODE data, rs3740958 overlaps transcription 
regulatory (both promoter and enhancer) marks in many cell types, although it is unclear 
whether they exist in mammary epithelial and myoepithelial cells. PRR5L rs3740958 is not 
in high LD with other SNPs in either the populations from the 1000 Genomes Project or in 
our study population, and has not been reported in studies in relation to the risk of cancer or 
other outcomes.
PIK3R1 encodes an 85 kD regulatory subunit of PI3K. PI3K plays an important role in the 
metabolic actions of insulin, and variants in this gene have been associated with insulin 
resistance and type 2 diabetes [28,29]. The variant allele of PIK3R1 rs7713645 has been 
linked to a higher BMI and elevated glucose levels in European women [30]. In our study, 
however, the SNP variant was associated with a decreased risk of breast cancer in AA 
women. It is noteworthy that the risk associated with this SNP may differ by the ER status of 
tumors. The decreased risk was mainly driven by ER+ tumors (OR=0.59, 95% CI=0.32–
1.09). However, for ER− breast cancer, the SNP was associated with a non-significant 
increased risk (OR=2.14, 95% CI=0.62–7.35; P-heterogeneity=0.09; Supplementary Table 
2). Because the risk allele (C) is the major allele in AA women, it is important to confirm 
whether the variant is associated with an increased risk of ER− breast cancer.
CDKAL1 rs9368197 was the only SNP associated with breast cancer risk in both EA and 
AA women. However, the direction of association was heterogeneous across the two 
populations. CDKAL1 encodes a subunit of cyclin-dependent protein kinase 5 (CDK5), 
involving post-transcriptional RNA modification [31]. CDK5 is overexpressed in breast 
cancer [32]. Several variants in CDKAL1 have been found to be associated with type 2 
diabetes and obesity [33,34]. CDKAL1 rs9368197 potentially confers adaptations in energy-
balance regulation in East Asians [35]. As we cannot eliminate the possibility that our 
findings were due to chance, whether the SNP in relation to breast cancer etiology differs 
between racial groups requires further research.
We observed that the association of FRAP1 rs12125777 with increased breast cancer risk 
was stronger in EA women with overweight or obese and greater weight gain than those 
with normal BMI and less weight gain. These findings provide some evidence for our 
hypothesis that the mTOR pathway, which is promoted by positive energy imbalance and 
increased growth factors associated with obesity, plays a role in the development of breast 
cancer. In animal models, an over-activated mTOR pathway due to obesity accelerates breast 
tumor growth [36]. A necessary next step in exploring the role of FRAP1 rs12125777 is to 
confirm whether the SNP or its mapped region has any functional impact on the mTOR 
pathway among EA women. Because among EA women, the positive association between 
obesity and breast cancer risk was more prominent for ER+ and postmenopausal breast 
cancer than ER− and pre-menopausal breast cancer [2], we explored effect modification of 
body size and weight gain according to ER subtype and menopausal status. In this 
exploratory analysis, the effect modification on FRAP1 rs12125777 remained significant for 
ER+ breast cancer, although the association seemed to be weaker than for ER− 
(Supplementary Table 4). Also, the SNP-breast cancer association appeared to be larger in 
postmenopausal women with BMI ≥30 kg/m2 (for all breast cancer ORGA/AA vs. GG=12.5, 
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95% CI=1.42–110) than premenopausal obese women (ORGA/AA vs. GG=5.05, 95% 
CI=0.94–27.2; data not shown). These risk estimates are likely inflated by chance due to 
small number of cases in the exposure group (the GA and AA genotypes) after stratification, 
but the data provide some hints that the mTOR pathway may be important for ER+ and 
postmenopausal breast cancer risk in EA women. A larger study is warranted to confirm 
these observations. For AA women, however, it was less clear whether the SNP can be 
influenced by body size and weight gain. Because our investigation on effect modification 
was restricted to a small number of SNPs with significant main effects, we may have missed 
risk SNPs or loci that would interact with body size among AA women.
Different associations of genetic variants with breast cancer between EA and AA in terms of 
strength or direction are commonly observed [37,38]. In the current study, none of the SNPs 
examined were significantly associated with breast cancer risk in both EA and AA women 
and the directions of associations for two SNPs in PRR5L and CDKAL1 were different 
between the two groups. The underlying reasons of these racial differences in genetic 
associations are likely multifactorial. As the LD structures are distinct between EA and AA 
women [39], with the SNP tagging approach, it is possible that the studied SNPs are linked 
to the causal variants only in either EA or AA women, but not both. Also, the often-observed 
differences in frequencies of minor alleles between EA and AA women can lead to 
differences in statistical power and thus true associations may not be observed. Our analysis 
on effect modification by body size also suggests different results across the two racial 
groups. In addition to the differences in genetic structures between populations, the 
relationships of body size with body composition are also different between EA and AA 
women. For example, for a given amount of body fat, which is correlated with BMI [40], EA 
women tend to have more visceral adipose tissue (and less subcutaneous adipose tissue), 
than AA women [41]. Visceral adipose tissue has been known to be active in signaling the 
insulin-like growth factor pathway [42], and potentially, the mTOR pathway [43]. Thus, it is 
possible that the measurements of body size represent these factors to different extents 
among EA and AA women and contribute to the heterogeneous effect modification of body 
size in our study.
In the effect modification analysis, we mutually adjusted for BMI, WHR, and weight gain to 
simultaneously account for the effects of each of the variables. However, these three 
variables are likely correlated with each other and thus the analysis may be subject to 
multicollinearity and the 95% CIs might have been inflated. We examined this issue by 
estimating the variance inflation factor (VIF) using linear regression; the VIFs were 2.26 for 
BMI, 1.18 for WHR, and 2.18 for weight gain variables. Thus, the potential inflation of 
standard errors (square root of VIF) for risk estimates due to the multicollinearity is likely 
limited, except for BMI. Although the 95% CIs of the genetic association in the strata of 
BMI are wider in the mutual adjustment model than in the model without the mutual 
adjustment, both models show significant effect modification.
Our study has several strengths. This study is a more comprehensive evaluation of mTOR 
pathway SNPs in relation to breast cancer risk than most previous studies [13,14]. The 
approximately equal number of EA and AA women in the WCHS allows for investigations 
of etiological factors of breast cancer within EA and AA women separately. This is 
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important because the distribution of breast cancer subtypes is different between these two 
populations and etiological factors may contribute to breast cancer risk differently. Also, 
WCHS collected in-depth information on covariates and most anthropometric measurements 
were taken by trained staff and were thus less prone to measurement error than self-report.
Several limitations should be noted. First, SNPs identified as being related to breast cancer 
risk in our study may not be causal, as the discovery of causal SNPs requires fine mapping 
efforts. The prioritized or functional SNPs that were not significant after the correction of 
multiple comparisons warrant further confirmation. Second, the information on ER status 
relied on pathology reports from different institutions, but any misclassification is unlikely 
to differ by genotype. Third, case-control studies are subject to selection bias, whereby 
controls do not adequately represent the source population from which the cases arose. To 
improve representativeness, we recruited AA controls from communities to supplement 
those recruited using random digit dialing [18]. In addition, the number of breast cancer 
cases was small within strata of body size and weight gain, resulting in wide 95% CIs and 
potentially inflated risk estimates.
In conclusion, we observed associations with breast cancer risk in either EA or AA women 
for SNPs in FRAP1, RPTOR, PIK3R1, and PRR5L in the mTOR pathway and an obesity-
linked SNP in CDKAL1. We cannot eliminate the possibility that the associations of FRAP1 
rs12125777 and RPTOR rs9900506 in EA women might be due to the elevated false positive 
rate from multiple comparisons. The association of SNP of FRAP1 rs12125777 with breast 
cancer risk in EA women may be modified by body size and weight gain. Contingent on 
confirmation and validation, our findings suggest that carcinogenic signaling related to the 
mTOR pathway may differentially influence breast cancer risk among EA and AA women.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Overview of the mTOR pathway
Abbreviations: 4E-BP1, 4E-binding protein-1; eIF-4E, eukaryotic initiation factor-4E; 
EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER2, receptor tyrosine-
protein kinase erbB-2; IGF-R1, insulin-like growth factor 1 receptor; IRS, insulin receptor 
substrate; PRAS40, proline-rich Akt substrate 40 kDa; PTEN, phosphatase and tensin 
homolog; S6, 40S ribosomal protein; S6K1, S6 kinase 1
Cheng et al. Page 15
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cheng et al. Page 16
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f p
ar
tic
ip
an
ts 
in
 th
e 
W
o
m
en
’s
 C
irc
le
 o
f H
ea
lth
 S
tu
dy
 (W
CH
S)
, 2
00
2–
20
11
C
ha
ra
ct
er
ist
ic
s
Eu
ro
pe
an
 A
m
er
ic
an
A
fr
ic
an
 A
m
er
ic
an
C
as
es
 (n
=6
45
)1
C
on
tr
o
ls 
(n
=6
41
)
P-
va
lu
e2
C
as
es
 (n
=6
18
)
C
on
tr
o
ls 
(n
=7
41
)
P-
va
lu
e2
A
ge
 (y
ea
r),
 m
ea
n (
SD
)
52
.0
 (1
0.1
)
49
.7
 (8
.7)
<
0.
00
1
51
.4
(10
.4)
48
.6
 (9
.4)
<
0.
00
1
Pe
rc
en
t E
ur
op
ea
n 
an
ce
str
y,
 
m
ea
n
 (S
D)
97
 (8
)
99
 (4
)
<
0.
00
1
14
 (1
6)
14
 (1
4)
0.
97
M
en
op
au
sa
l s
ta
tu
s, 
n 
(%
)
0.
46
0.
03
3
 
Pr
em
en
op
au
sa
l
33
9 
(52
.6)
35
0 
(54
.6)
30
6 
(49
.5)
41
0 
(55
.3)
 
Po
st
m
en
op
au
sa
l
30
6 
(47
.4)
29
1 
(45
.4)
31
2 
(50
.5)
33
1 
(44
.7)
Fa
m
ily
 h
ist
or
y,
 
n
 (%
)
0.
00
1
0.
15
 
N
o
48
9 
(75
.8)
53
3 
(83
.2)
52
9 
(85
.6)
65
4 
(88
.3)
 
Ye
s
15
6 
(24
.2)
10
8 
(16
.8)
89
 (1
4.4
)
87
 (1
1.7
)
Ed
uc
at
io
n,
 n
 (%
)
<
0.
00
1
0.
19
 
H
ig
h 
sc
ho
ol
 o
r b
el
ow
13
2 
(20
.5)
72
 (1
1.2
)
27
8 
(45
.0)
29
4 
(39
.7)
 
So
m
e 
co
lle
ge
14
0 
(21
.7)
11
6 
(18
.1)
16
6 
(26
.9)
20
3 
(27
.4)
 
Co
lle
ge
 g
ra
du
at
e
19
6 
(30
.4)
20
8 
(32
.5)
10
7 
(17
.3)
14
9 
(20
.1)
 
Po
st
-g
ra
du
at
e 
de
gr
ee
17
7 
(27
.4)
24
5 
(38
.2)
67
 (1
0.8
)
95
 (1
2.8
)
H
ist
or
y 
of
 b
en
ig
n 
br
ea
st 
di
se
as
e,
 n
 (%
)
0.
00
1
<
0.
00
1
 
N
o
38
0 
(58
.9)
43
4 
(67
.7)
42
6 
(68
.9)
58
5 
(79
.0)
 
Ye
s
26
5 
(41
.1)
20
7 
(32
.3)
19
2 
(31
.1)
15
6 
(21
.0)
A
ge
 a
t m
en
ar
ch
e 
(ye
ar)
, m
ea
n (
SD
)
12
.5
 (1
.5)
12
.6
 (1
.6)
0.
36
12
.5
 (1
.8)
12
.5
 (1
.8)
0.
39
Pa
rit
y 
(nu
mb
er 
of 
liv
e 
bi
rth
s),
 n 
(%
)
0.
36
0.
84
 
N
ul
lip
ar
ou
s
20
2 
(31
.3)
18
2 
(28
.4)
10
0 
(16
.2)
11
2 
(15
.1)
 
1
10
5 
(16
.3)
12
3 
(19
.2)
13
6 
(22
.0)
17
3 
(23
.4)
 
2
20
2 
(31
.3)
21
2 
(33
.1)
17
1 
(27
.7)
19
5 
(26
.3)
 
≥3
13
6 
(21
.1)
12
4 
(19
.3)
21
1 
(34
.1)
26
1 
(35
.2)
B
re
as
tfe
ed
in
g 
sta
tu
s (
am
on
g p
aro
us
 w
o
m
en
), n
 (%
)
0.
00
8
0.
65
 
N
o
16
6 
(37
.5)
13
4 
(29
.2)
25
9 
(50
.0)
32
3 
(51
.4)
 
Ye
s
27
7 
(62
.5)
32
5 
(70
.8)
25
9 
(50
.0)
30
6 
(48
.6)
Ci
ga
re
tte
 s
m
ok
in
g 
sta
tu
s
0.
22
<
0.
00
1
 
N
ev
er
 s
m
o
ke
r
33
2 
(51
.5)
35
8 
(55
.9)
38
7 
(62
.6)
42
4 
(57
.2)
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cheng et al. Page 17
C
ha
ra
ct
er
ist
ic
s
Eu
ro
pe
an
 A
m
er
ic
an
A
fr
ic
an
 A
m
er
ic
an
C
as
es
 (n
=6
45
)1
C
on
tr
o
ls 
(n
=6
41
)
P-
va
lu
e2
C
as
es
 (n
=6
18
)
C
on
tr
o
ls 
(n
=7
41
)
P-
va
lu
e2
 
Fo
rm
er
 s
m
o
ke
r
23
6 
(36
.6)
20
6 
(32
.1)
14
7 
(23
.8)
14
0 
(18
.9)
 
Cu
rre
nt
 sm
ok
er
77
 (1
1.9
)
77
 (1
2.0
)
84
 (1
3.6
)
17
7 
(23
.9)
B
od
y 
m
as
s i
nd
ex
 (k
g/m
2 ),
 n 
(%
)
0.
74
0.
82
 
<
25
29
9 
(46
.4)
29
2 
(45
.5)
11
9 
(19
.3)
13
3 
(17
.9)
 
25
 –
 <
30
16
5 
(25
.6)
17
6 
(27
.5)
17
7 
(28
.6)
21
4 
(28
.9)
 
≥3
0
18
1 
(28
.0)
17
3 
(27
.0)
32
2 
(52
.1)
39
4 
(53
.2)
W
ai
st-
to
-h
ip
 ra
tio
0.
81
0.
55
 
≤0
.8
5
37
7 
(59
.2)
38
0 
(59
.8)
25
2 
(41
.5)
31
7 
(43
.1)
 
>
0.
85
26
0 
(40
.8)
25
5 
(40
.2)
35
5 
(58
.5)
41
8 
(56
.9)
W
ei
gh
t g
ai
n 
fro
m
 a
ge
 2
0 
(lb
.
), n
 (%
)
0.
85
0.
23
 
<
10
15
0 
(23
.4)
15
7 
(24
.6)
61
 (1
0.2
)
75
 (1
0.3
)
 
10
 –
 <
25
10
6 
(16
.5)
95
 (1
4.9
)
49
 (8
.2)
60
 (8
.2)
 
25
 –
 <
35
12
9 
(20
.1)
12
6 
(19
.8)
82
 (1
3.7
)
13
0 
(17
.8)
 
≥3
5
25
7 
(40
.0)
25
9 
(40
.7)
40
6 
(67
.9)
46
5 
(63
.7)
Es
tro
ge
n 
re
ce
pt
or
 (E
R)
 St
atu
s, 
n (
%)
3
 
Po
sit
iv
e
38
0 
(82
.8)
–
32
4 
(68
.5)
–
 
N
eg
at
iv
e
79
 (1
7.2
)
–
14
9 
(31
.5)
–
A
bb
re
v
ia
tio
ns
: n
, n
um
be
r; 
SD
, s
ta
nd
ar
d 
de
v
ia
tio
n
1 N
um
be
r m
ay
 n
ot
 a
dd
 u
p 
to
 th
e 
to
ta
l n
um
be
r d
ue
 to
 m
iss
in
g 
va
lu
es
2 P
-v
al
ue
 w
er
e 
es
tim
at
ed
 b
y 
t-t
es
t f
or
 c
on
tin
uo
us
 v
ar
ia
bl
es
 a
nd
 C
hi
-s
qu
ar
e 
te
st 
fo
r c
at
eg
or
ic
al
 v
ar
ia
bl
es
3 E
R
 st
at
us
 w
as
 a
v
ai
la
bl
e 
fo
r 4
59
 (7
1.2
%)
 E
A 
ca
ses
 an
d 4
73
 (7
6.5
%)
 A
A 
ca
ses
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cheng et al. Page 18
Ta
bl
e 
2
A
ss
oc
ia
tio
n 
of
 m
TO
R 
pa
th
w
ay
 S
N
Ps
 w
ith
 b
re
as
t c
an
ce
r r
isk
1,
2
G
en
e
SN
P
G
en
ot
yp
e
Eu
ro
pe
an
 A
m
er
ic
an
A
fr
ic
an
 A
m
er
ic
an
# 
C
as
e/
C
on
tr
o
l
O
R
 (9
5%
 C
I)
P-
tr
en
d3
P A
C
T4
# 
C
as
e/
C
on
tr
o
l
O
R
 (9
5%
 C
I)
P-
tr
en
d3
P A
C
T4
P-
in
te
ra
ct
io
n5
FR
A
P1
rs
12
12
57
77
 (i
ntr
on
)
G
G
58
4/
60
4
1.
00
0.
02
0
0.
17
51
5/
62
7
1.
00
0.
82
N
A
7
0.
08
G
A
59
/3
5
1.
69
 (1
.07
–2
.66
)
10
3/
10
9
1.
14
 (0
.84
–1
.55
)
A
A
2/
1
1.
62
 (0
.13
–1
9.4
6)
0/
5
–
G
A
/A
A
 v
s. 
G
G
61
/3
6
1.
69
 (1
.08
–2
.64
)
10
3/
11
4
1.
09
 (0
.80
–1
.48
)
RP
TO
R
rs
99
00
50
66
 
(in
tro
n)
A
A
21
6/
19
6
1.
00
0.
04
2
0.
89
31
9/
38
6
1.
00
0.
60
N
A
7
0.
29
A
G
32
9/
31
1
0.
97
 (0
.74
–1
.26
)
25
4/
29
5
1.
00
 (0
.79
–1
.27
)
G
G
99
/1
33
0.
68
 (0
.48
–0
.95
)
45
/6
0
0.
87
 (0
.53
–1
.33
)
G
G
/G
A
 v
s. 
A
A
42
8/
44
4
0.
88
 (0
.69
–1
.12
)
30
1/
35
5
0.
98
 (0
.78
–1
.22
)
RP
TO
R
rs
38
17
29
36
 
(in
tro
n)
G
G
42
1/
41
4
1.
00
0.
72
N
A
7
27
7/
28
6
1.
00
0.
04
4
0.
97
0.
20
G
A
19
9/
19
6
1.
01
 (0
.79
–1
.31
)
27
2/
36
1
0.
80
 (0
.63
–1
.01
)
A
A
23
/2
8
0.
79
 (0
.43
–1
.46
)
67
/8
9
0.
75
 (0
.51
–1
.08
)
A
A
/G
A
 v
s. 
G
G
22
2/
22
4
0.
99
 (0
.77
–1
.26
)
33
9/
45
0
0.
79
 (0
.63
–0
.99
)
PI
K
3R
1
rs
77
13
64
5 
(in
tro
n)
A
A
19
1/
17
2
1.
00
0.
19
N
A
7
37
/2
7
1.
00
0.
00
3
0.
04
1
0.
07
A
C
31
4/
32
3
0.
87
 (0
.67
–1
.15
)
21
2/
22
5
0.
77
 (0
.44
–1
.34
)
CC
14
0/
14
5
0.
80
 (0
.58
–1
.12
)
36
6/
48
8
0.
56
 (0
.33
–0
.97
)
CC
/A
C 
vs
. A
A
45
4/
46
8
0.
85
 (0
.66
–1
.10
)
57
8/
71
3
0.
63
 (0
.37
–1
.08
)
PR
R5
L
rs
37
40
95
8 
(sy
no
ny
m
ou
s c
od
in
g)
A
A
47
7/
52
4
1.
00
<
0.
00
1
0.
00
5
47
1/
53
6
1.
00
0.
10
N
A
7
0.
00
1
G
A
15
3/
10
7
1.
69
 (1
.26
–2
.27
)
13
3/
18
3
0.
81
 (0
.62
–1
.06
)
G
G
14
/1
0
1.
87
 (0
.78
–4
.50
)
14
/2
0
0.
76
 (0
.37
–1
.55
)
G
G
/G
A
 v
s. 
A
A
16
7/
11
7
1.
71
 (1
.29
–2
.27
)
14
7/
20
3
0.
81
 (0
.63
–1
.04
)
CD
KA
L1
rs
93
68
19
7 
(in
tro
n)
CC
30
5/
33
5
1.
00
0.
03
2
N
A
8
63
4/
61
3
1.
00
0.
01
5
N
A
8
0.
00
5
A
C
26
9/
26
0
1.
11
 (0
.87
–1
.42
)
80
/1
22
0.
74
 (0
.54
–1
.02
)
A
A
69
/4
6
1.
66
 (1
.08
–2
.54
)
0/
6
–
A
A
/A
C 
vs
. C
C
33
8/
30
6
1.
19
 (0
.94
–1
.50
)
80
/1
28
0.
70
 (0
.51
–0
.97
)
A
bb
re
v
ia
tio
ns
: N
A
, n
ot
 a
pp
lic
ab
le
; O
R,
 o
dd
s r
at
io
; 9
5%
CI
, 9
5%
 co
nf
id
en
ce
 in
te
rv
al
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cheng et al. Page 19
1 O
nl
y 
sig
ni
fic
an
t S
N
Ps
 in
 e
ith
er
 ra
ci
al
 g
ro
up
 a
re
 p
re
se
nt
ed
.
2 A
dju
ste
d f
or 
ag
e a
t d
iag
no
sis
 (c
on
tin
uo
us)
, p
rop
ort
ion
 of
 Eu
rop
ean
 an
ces
try
 (c
on
tin
uo
us)
, e
du
cat
ion
 (le
ss 
tha
n h
igh
 sc
ho
ol,
 hi
gh
 sc
ho
ol,
 co
lle
ge
 a
nd
 g
ra
du
at
e 
sc
ho
ol
), b
od
y m
ass
 in
de
x
 (<
25
, 2
5–
<3
0, 
≥3
0 
kg
/m
2 )
, fa
m
ily
 h
ist
or
y 
of
 b
re
as
t c
an
ce
r, 
hi
sto
ry
 o
f b
en
ig
n 
br
ea
st 
di
se
as
e,
 a
ge
 a
t m
en
ar
ch
e 
(co
nti
nu
ou
s),
 pa
rit
y, 
br
ea
stf
ee
di
ng
 (y
es,
 no
, n
ull
ipa
rou
s),
 m
en
op
au
sal
 st
atu
s, 
an
d s
mo
kin
g s
tat
us
 (c
urr
en
t, f
orm
er,
 
n
ev
er
).
3 P
-v
al
ue
s f
or
 tr
en
d 
w
er
e 
ca
lc
ul
at
ed
 b
y 
co
di
ng
 v
ar
ia
nt
 a
lle
le
s b
as
ed
 o
n 
th
e 
nu
m
be
r o
f r
ar
e 
al
le
le
s (
0, 
1, 
2) 
an
d a
na
lyz
ed
 as
 a 
co
nti
nu
ou
s v
ar
ia
bl
e 
in
 re
gr
es
sio
n.
4 P
 v
al
ue
s a
dju
ste
d f
or 
co
rre
lat
ed
 te
sts
5 P
 fo
r i
nt
er
ac
tio
n 
be
tw
ee
n 
SN
P 
an
d 
ra
ce
6 S
N
Ps
 w
ith
 p
ot
en
tia
l r
eg
ul
at
or
y 
fu
nc
tio
n:
 th
e 
Re
gu
lo
m
eD
B 
sc
or
e 
is 
3a
 fo
r R
PT
OR
 
rs
99
00
50
6 
an
d 
2b
 fo
r R
PT
OR
 
rs
38
17
29
3 
(r2
=
0.
23
)
7 P
A
CT
 
w
as
 n
o
t a
pp
lic
ab
le
 b
ec
au
se
 n
om
in
al
 P
>0
.0
5
8 P
A
CT
 
w
as
 n
o
t a
pp
lic
ab
le
 b
ec
au
se
 th
e 
ge
ne
 h
ad
 o
nl
y 
1 
SN
P 
te
ste
d
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cheng et al. Page 20
Ta
bl
e 
3
Ef
fe
ct
 m
od
ifi
ca
tio
n 
of
 b
od
y 
siz
e 
an
d 
w
ei
gh
t g
ai
n 
on
 th
e 
as
so
ci
at
io
n 
of
 F
RA
P1
 
rs
12
12
57
77
 g
en
ot
yp
e w
ith
 b
re
as
t c
an
ce
r1
Eu
ro
pe
an
 A
m
er
ic
an
A
fr
ic
an
 A
m
er
ic
an
G
G
G
A
/A
A
G
G
G
A
/A
A
# 
C
as
e/
C
on
tr
o
l
O
R
 (r
ef
.
)
# 
C
as
e/
C
on
tr
o
l
O
R
 (9
5%
 C
I)
P-
in
te
ra
ct
io
n
# 
C
as
e/
C
on
tr
o
l
O
R
 (r
ef
.
)
# 
C
as
e/
C
on
tr
o
l
O
R
 (9
5%
 C
I)
P-
in
te
ra
ct
io
n
B
od
y 
m
as
s i
nd
ex
 
(kg
/m
2 )
<
25
27
0/
26
0
1.
00
23
/2
4
0.
85
 (0
.45
–1
.61
)
0.
00
7
91
/1
13
1.
00
20
/2
0
1.
54
 (0
.72
–3
.27
)
0.
29
25
 –
 <
30
14
5/
16
7
1.
00
17
/8
2.
37
 (0
.91
–6
.13
)
13
4/
17
4
1.
00
37
/3
7
1.
36
 (0
.79
–2
.33
)
≥3
0
15
8/
16
7
1.
00
21
/4
7.
69
 (2
.11
–2
8.0
)
26
4/
32
3
1.
00
42
/5
7
0.
87
 (0
.55
–1
.39
)
W
ai
st-
to
-h
ip
 ra
tio
≤0
.8
5
33
9/
35
3
1.
00
35
/2
5
1.
28
 (0
.72
–2
.26
)
0.
15
20
7/
26
0
1.
00
42
/5
3
1.
03
 (0
.64
–1
.64
)
0.
57
>
0.
85
23
4/
24
1
1.
00
26
/1
1
2.
75
 (1
.27
–5
.94
)
28
2/
35
0
1.
00
57
/6
1
1.
17
 (0
.77
–1
.77
)
W
ei
gh
t g
ai
n 
fro
m
 
ag
e 
20
 (l
b.)
<
10
2
13
4/
14
0
1.
00
13
/1
3
1.
07
 (0
.44
–2
.58
)
0.
02
1
49
/6
5
1.
00
10
/1
0
1.
49
 (0
.47
–4
.73
)
0.
37
10
 –
 <
25
96
/8
7
1.
00
9/
8
0.
96
 (0
.32
–2
.92
)
37
/5
1
1.
00
11
/9
2.
13
 (0
.53
–8
.51
)
25
 –
 <
35
11
5/
11
8
1.
00
13
/7
2.
22
 (0
.78
–6
.35
)
66
/1
09
1.
00
15
/2
1
1.
26
 (0
.58
–2
.77
)
≥3
5
22
8/
24
9
1.
00
26
/8
3.
34
 (1
.42
–7
.85
)
33
7/
38
5
1.
00
63
/7
4
0.
96
 (0
.65
–1
.41
)
1 A
dju
ste
d f
or 
ag
e a
t d
iag
no
sis
, p
rop
ort
ion
 of
 Eu
rop
ean
 an
ces
try
,
 
ed
uc
at
io
n,
 fa
m
ily
 h
ist
or
y 
of
 b
re
as
t c
an
ce
r, 
hi
sto
ry
 o
f b
en
ig
n 
br
ea
st 
di
se
as
e,
 a
ge
 a
t m
en
ar
ch
e,
 p
ar
ity
,
 
br
ea
stf
ee
di
ng
 st
at
us
, m
en
op
au
sa
l s
ta
tu
s, 
an
d 
sta
tu
s o
f c
ig
ar
et
te
 s
m
ok
in
g.
 M
od
el
s w
er
e 
fu
rth
er
 m
ut
ua
lly
 a
dju
ste
d f
or 
the
 bo
dy
 si
ze 
an
d w
eig
ht 
ga
in
 v
ar
ia
bl
es
. F
o
r 
ex
am
pl
e,
 O
Rs
 fo
r B
M
I w
er
e 
ad
jus
ted
 fo
r W
HR
 an
d w
eig
ht 
ga
in
 fr
om
 a
ge
 2
0.
2 I
nc
lu
di
ng
 n
o 
ch
an
ge
 in
 w
ei
gh
t o
r w
ei
gh
t l
os
s.
Cancer Causes Control. Author manuscript; available in PMC 2017 August 01.
